John G. Gribben – författare

Written by authors from the world''s most prominent cancer centers, Chronic Lymphocytic Leukemia supplies a comprehensive, up-to-date picture of CLL and how to better treat patients inflicted with the disease.New information on developments in the molecular pathogenesis of this disease impacts how physicians approach and treat patients with CLL. The various predisposing factors for the disease are addressed along with current and future treatment modalities and recommended standards of care.

The new and fully-revised volume of hematologic molecular biology for practicing and trainee hematologists

Molecular Hematology is a comprehensive resource for hematologists to increase their understanding of the molecular basis of various blood diseases, their pathogeneses, and current and emerging molecular research and therapies. The impact of molecular research on the field of hematology is significant—molecular techniques are continuing to play a central role in in the diagnosis and treatment of blood diseases. Molecular characterization of genes and proteins has increased our comprehension of the causes of hematological diseases and led to the development of new drug therapies and recombinant proteins.

Now in its fourth edition, Molecular Hematology has been thoroughly revised and updated to reflect current advances in molecular research. Chapters introduce and summarize specific disorders, such as hemophilia, anemia, and multiple myeloma, and illustrate the impact of molecular research on their diagnoses and treatments. Contributions written by respected clinicians and researchers offer accessible coverage of topics including lymphoma genetics, molecular coagulation and thrombophilia, platelet disorders, pharmacogenomics, and many others.

Demonstrates the clinical relevance of molecular biology in hematology Provides overviews of recent advances in cancer-cell biology, with an emphasis on leukemia and lymphoma Offers new and updated chapters written by an international team of experts in the field Presents new full-color charts, graphs, and illustrations Includes access to a Wiley Companion Digital Edition providing search across the book, downloadable illustrations and notation tools

Molecular Hematology is an essential volume for both trainee and practicing hematologists and oncologists, molecular biologists, and research scientists working in the field of hematology.

The new and fully-revised volume of hematologic molecular biology for practicing and trainee hematologists

Molecular Hematology is a comprehensive resource for hematologists to increase their understanding of the molecular basis of various blood diseases, their pathogeneses, and current and emerging molecular research and therapies. The impact of molecular research on the field of hematology is significant—molecular techniques are continuing to play a central role in in the diagnosis and treatment of blood diseases. Molecular characterization of genes and proteins has increased our comprehension of the causes of hematological diseases and led to the development of new drug therapies and recombinant proteins.

Now in its fourth edition, Molecular Hematology has been thoroughly revised and updated to reflect current advances in molecular research. Chapters introduce and summarize specific disorders, such as hemophilia, anemia, and multiple myeloma, and illustrate the impact of molecular research on their diagnoses and treatments. Contributions written by respected clinicians and researchers offer accessible coverage of topics including lymphoma genetics, molecular coagulation and thrombophilia, platelet disorders, pharmacogenomics, and many others.

Demonstrates the clinical relevance of molecular biology in hematology Provides overviews of recent advances in cancer-cell biology, with an emphasis on leukemia and lymphoma Offers new and updated chapters written by an international team of experts in the field Presents new full-color charts, graphs, and illustrations Includes access to a Wiley Companion Digital Edition providing search across the book, downloadable illustrations and notation tools

Molecular Hematology is an essential volume for both trainee and practicing hematologists and oncologists, molecular biologists, and research scientists working in the field of hematology.

Presents timely and authoritative information on the development of precision cancer therapies as applied to hematologic malignancies The Precision Cancer Therapies series focuses on how to understand and translate fundamental basic science into information that can be directly applied to patients to advance care. Each volume of the series integrates the relevant biological concepts and principles necessary for translating this science to practitioners of this science. Precision Cancer Therapies, Volume Two, focuses on sophisticated immunotherapies targeting cancers affecting the blood, bone marrow, and lymph nodes. Edited and authored by the foremost authorities in the field, this comprehensive reference text covers targeting of cell surface receptors, antibody-drug conjugates (ADC), targeting immune checkpoint, targeting macrophages, EBV-directed immunotherapies, tumor-associated antigens (TAA), and chimeric antigen receptor T-cells (CAR-T). Divided into nine sections, Volume Two includes an overview of the history of immunotherapy development in cancer, as well as a concluding section addressing the mechanistic basis and role of immunomodulatory drugs, analytical tools to quantitate immune-mediated effects, and other topics in immunotherapy. Chapters on specific therapeutics or therapeutic classes include a basic explanation of the underlying pathway and target, the pharmacology of the drug/class, relevant preclinical and clinical data, and discussion of clinical management and potential predictive biomarkers of response. This book also: Delivers a definitive, state-of-the-art review of the relevant biology and its importance in the broader context of cancer biologyFocuses on agents that mediate cell killing in lymphoma through a variety of immunologic mechanismsCovers FDA-approved drugs and their indications, as well as drugs currently in developmentProvides information on monotherapy and combination therapy, summary tables of trials, and discussion of toxicity and efficacyIncludes boxed sections highlighting major unique points about the information in the chapter Precision Cancer Therapies, Volume Two: Immunologic Approaches for the Treatment of Lymphoid Malignancies, From Concept to Practice is an indispensable resource for medical, scientific, and allied medical professionals, advanced students, and interested general readers with background knowledge in the subject.

Presents timely and authoritative information on the development of precision cancer therapies as applied to hematologic malignancies

The Precision Cancer Therapies series focuses on how to understand and translate fundamental basic science into information that can be directly applied to patients to advance care. Each volume of the series integrates the relevant biological concepts and principles necessary for translating this science to practitioners of this science.

Precision Cancer Therapies, Volume Two, focuses on sophisticated immunotherapies targeting cancers affecting the blood, bone marrow, and lymph nodes. Edited and authored by the foremost authorities in the field, this comprehensive reference text covers targeting of cell surface receptors, antibody-drug conjugates (ADC), targeting immune checkpoint, targeting macrophages, EBV-directed immunotherapies, tumor-associated antigens (TAA), and chimeric antigen receptor T-cells (CAR-T).

Divided into nine sections, Volume Two includes an overview of the history of immunotherapy development in cancer, as well as a concluding section addressing the mechanistic basis and role of immunomodulatory drugs, analytical tools to quantitate immune-mediated effects, and other topics in immunotherapy. Chapters on specific therapeutics or therapeutic classes include a basic explanation of the underlying pathway and target, the pharmacology of the drug/class, relevant preclinical and clinical data, and discussion of clinical management and potential predictive biomarkers of response. This book also:

Delivers a definitive, state-of-the-art review of the relevant biology and its importance in the broader context of cancer biology Focuses on agents that mediate cell killing in lymphoma through a variety of immunologic mechanisms Covers FDA-approved drugs and their indications, as well as drugs currently in development Provides information on monotherapy and combination therapy, summary tables of trials, and discussion of toxicity and efficacy Includes boxed sections highlighting major unique points about the information in the chapter

Precision Cancer Therapies, Volume Two: Immunologic Approaches for the Treatment of Lymphoid Malignancies, From Concept to Practice is an indispensable resource for medical, scientific, and allied medical professionals, advanced students, and interested general readers with background knowledge in the subject.

Presents timely and authoritative information on the development of precision cancer therapies as applied to hematologic malignancies

The Precision Cancer Therapies series focuses on how to understand and translate fundamental basic science into information that can be directly applied to patients to advance care. Each volume of the series integrates the relevant biological concepts and principles necessary for translating this science to practitioners of this science.

Precision Cancer Therapies, Volume Two, focuses on sophisticated immunotherapies targeting cancers affecting the blood, bone marrow, and lymph nodes. Edited and authored by the foremost authorities in the field, this comprehensive reference text covers targeting of cell surface receptors, antibody-drug conjugates (ADC), targeting immune checkpoint, targeting macrophages, EBV-directed immunotherapies, tumor-associated antigens (TAA), and chimeric antigen receptor T-cells (CAR-T).

Divided into nine sections, Volume Two includes an overview of the history of immunotherapy development in cancer, as well as a concluding section addressing the mechanistic basis and role of immunomodulatory drugs, analytical tools to quantitate immune-mediated effects, and other topics in immunotherapy. Chapters on specific therapeutics or therapeutic classes include a basic explanation of the underlying pathway and target, the pharmacology of the drug/class, relevant preclinical and clinical data, and discussion of clinical management and potential predictive biomarkers of response. This book also:

Delivers a definitive, state-of-the-art review of the relevant biology and its importance in the broader context of cancer biology Focuses on agents that mediate cell killing in lymphoma through a variety of immunologic mechanisms Covers FDA-approved drugs and their indications, as well as drugs currently in development Provides information on monotherapy and combination therapy, summary tables of trials, and discussion of toxicity and efficacy Includes boxed sections highlighting major unique points about the information in the chapter

Precision Cancer Therapies, Volume Two: Immunologic Approaches for the Treatment of Lymphoid Malignancies, From Concept to Practice is an indispensable resource for medical, scientific, and allied medical professionals, advanced students, and interested general readers with background knowledge in the subject.

Written by authors from the world’s most prominent cancer centers, Chronic Lymphocytic Leukemia supplies a comprehensive, up-to-date picture of CLL and how to better treat patients inflicted with the disease.New information on developments in the molecular pathogenesis of this disease impacts how physicians approach and treat patients with CLL. The various predisposing factors for the disease are addressed along with current and future treatment modalities and recommended standards of care.Key features include: introduction by Kanti Rai, MD who developed the Rai Classification and Staging system used in CLL diagnosisCLL in relationship to gene expression profiling and molecular abnormalitiesfamilial clustering and gene predispositiontargeted therapy trialsclinical patient management based upon stage and progression of disease

Written by authors from the world''s most prominent cancer centers, Chronic Lymphocytic Leukemia supplies a comprehensive, up-to-date picture of CLL and how to better treat patients inflicted with the disease.New information on developments in the molecular pathogenesis of this disease impacts how physicians approach and treat patients with CLL. The various predisposing factors for the disease are addressed along with current and future treatment modalities and recommended standards of care.